米兰系统在颌下腺细针穿刺细胞学中的应用:国际多机构研究
该国际多机构回顾性研究将734例颌下腺细针穿刺(FNA)标本按米兰系统(MSRSGC)重新分类,并在333例(45.4%)有组织学随访的病例中计算各分类的恶性风险(ROM)。结果显示各分类ROM与腮腺FNA报道相似,但各机构间分类比例存在变异,提示MSRSGC可可靠应用于颌下腺FNA。
要点
- 颌下腺FNA按MSRSGC分类后,各分类的恶性风险与腮腺报道相似。
- 非诊断性、非肿瘤性、AUS、良性肿瘤、SUMP、可疑恶性、恶性的ROM分别为10.6%、7.5%、27.6%、3.2%、41.9%、82.3%、93.6%。
- 各机构间MSRSGC分类比例存在变异,但MSRSGC仍可可靠用于颌下腺FNA。
核心结论
- MSRSGC可可靠应用于颌下腺FNA,各分类恶性风险与腮腺FNA报道相似。
研究设计与样本
- 国际15家机构2013-2017年颌下腺FNA标本共734例,回顾性分配至MSRSGC分类。
主要发现
- 734例重新分类比例:非诊断性21.4%(0%-50%)、非肿瘤性24.2%(9.1%-53.6%)、AUS 6.7%(0%-14.3%)、良性肿瘤18.3%(0%-52.5%)、SUMP 12%(0%-37.7%)、可疑恶性3.5%(0%-12.5%)、恶性13.9%(2%-31.3%)。
- 333例有随访病例的恶性风险:非诊断性10.6%、非肿瘤性7.5%、AUS 27.6%、良性肿瘤3.2%、SUMP 41.9%、可疑恶性82.3%、恶性93.6%。
关键数值与推荐
- MSRSGC为6级诊断分类系统,附带恶性风险和管理推荐。
- 颌下腺FNA中炎症病变频率较高且恶性比例相对较高,可能影响ROM和管理。
临床怎么用
- 颌下腺FNA可参照MSRSGC分类评估恶性风险并指导管理。
- 需注意各机构间分类比例存在变异,报告时应结合临床。
局限性
- 回顾性研究设计。
- 仅45.4%病例有组织学随访,ROM计算基于随访子集。
- 各机构间MSRSGC分类比例存在变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) is a 6-tier diagnostic category system with associated risks of malignancy (ROMs) and management recommendations. Submandibular gland fine-needle aspiration (FNA) is uncommon with a higher frequency of inflammatory lesions and a higher relative proportion of malignancy, and this may affect the ROM and subsequent management. This study evaluated the application of the MSRSGC and the ROM for each diagnostic category for 734 submandibular gland FNAs. METHODS: Submandibular gland FNA cytology specimens from 15 international institutions (2013-2017) were retrospectively assigned to an MSRSGC diagnostic category as follows: nondiagnostic, nonneoplastic, atypia of undetermined significance (AUS), benign neoplasm, salivary gland neoplasm of uncertain malignant potential (SUMP), suspicious for malignancy (SM), or malignant. A correlation with the available histopathologic follow-up was performed, and the ROM was calculated for each MSRSGC diagnostic category. RESULTS: The case cohort of 734 aspirates was reclassified according to the MSRSGC as follows: nondiagnostic, 21.4% (0%-50%); nonneoplastic, 24.2% (9.1%-53.6%); AUS, 6.7% (0%-14.3%); benign neoplasm, 18.3% (0%-52.5%); SUMP, 12% (0%-37.7%); SM, 3.5% (0%-12.5%); and malignant, 13.9% (2%-31.3%). The histopathologic follow-up was available for 333 cases (45.4%). The ROMs were as follows: nondiagnostic, 10.6%; nonneoplastic, 7.5%; AUS, 27.6%; benign neoplasm, 3.2%; SUMP, 41.9%; SM, 82.3%; and malignant, 93.6%. CONCLUSIONS: This multi-institutional study shows that the ROM of each MSRSGC category for submandibular gland FNA is similar to that reported for parotid gland FNA, although the reported rates for the different MSRSGC categories were variable across institutions. Thus, the MSRSGC can be reliably applied to submandibular gland FNA.
引用
- Maleki Z, Baloch Z, Lu R, et al. Application of the Milan System for Reporting Submandibular Gland Cytopathology: An international, multi-institutional study. Cancer Cytopathol. 2019. PMID: 31050186. doi:10.1002/cncy.22135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。